Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
R&D pipeline
Our R&D pipeline includes the following:
- NP-500 (Insulin Resistance and Metabolic Disease)
- CFTR (cystic fibrosis transmembrane conductance regulator) inhibitors technology
- Polycystic Kidney Disease
- Pre-clinical screening (plant library)
 |
 |
 |